Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 13882
Country/Region: Kenya
Year: 2018
Main Partner: Children of God Relief Fund
Main Partner Program: NA
Organizational Type: FBO
Funding Agency: USAID
Total Funding: $1,807,295 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $0
Care: Orphans and Vulnerable Children (HKID) $649,484
Care: TB/HIV (HVTB) $0
Care: Pediatric Care and Support (PDCS) $0
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Testing: HIV Testing and Counseling (HVCT) $17,080
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $51,191
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $422,670
Treatment: Pediatric Treatment (PDTX) $666,870
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST 25-29, Female, Negative 2019 22
HTS_TST 25-29, Female, Negative 2019 64
HTS_TST 25-29, Male, Negative 2019 29
HTS_TST 25-29, Male, Negative 2019 104
HTS_TST 30-34, Female, Negative 2019 20
HTS_TST 30-34, Female, Negative 2019 72
HTS_TST 30-34, Male, Negative 2019 31
HTS_TST 30-34, Male, Negative 2019 123
HTS_TST 35-39, Female, Negative 2019 19
HTS_TST 35-39, Female, Negative 2019 24
HTS_TST 35-39, Male, Negative 2019 123
HTS_TST 35-39, Male, Negative 2019 43
HTS_TST 40-49, Female, Negative 2019 19
HTS_TST 40-49, Female, Negative 2019 20
HTS_TST 40-49, Male, Negative 2019 41
HTS_TST 40-49, Male, Negative 2019 40
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 2,936
HTS_TST Service Delivery Point (Facility) TB: 1-9, Negative 2019 13
HTS_TST Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 15
HTS_TST Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 14
HTS_TST Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 23
HTS_TST Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 28
HTS_TST Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 23
HTS_TST Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 28
HTS_TST Service Delivery Point (Facility) TB: 50+, Female, Negative 2019 18
HTS_TST Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 33
HTS_TST Service Delivery Point (Facility) VCT: <1, Negative 2019 34
HTS_TST Service Delivery Point (Facility) VCT: 1-9, Negative 2019 101
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2019 21
HTS_TST Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2019 21
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 244
HTS_TST Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 124
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 840
HTS_TST Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 396
HTS_TST Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 6
HTS_TST Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 21
HTS_TST_POS 25-29, Female, Positive 2019 3
HTS_TST_POS 25-29, Male, Positive 2019 4
HTS_TST_POS 30-34, Female, Positive 2019 3
HTS_TST_POS 30-34, Male, Positive 2019 7
HTS_TST_POS 35-39, Male, Positive 2019 7
HTS_TST_POS 40-49, Male, Positive 2019 2
HTS_TST_POS Service Delivery Point (Facility) VCT: <1, Positive 2019 7
HTS_TST_POS Service Delivery Point (Facility) VCT: 1-9, Positive 2019 19
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Female, Positive 2019 4
HTS_TST_POS Service Delivery Point (Facility) VCT: 10-14, Male, Positive 2019 3
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 14
HTS_TST_POS Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 5
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 40
HTS_TST_POS Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 20
HTS_TST_POS Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 1
OVC_SERV Age/Sex: <1 2019 151
OVC_SERV Age/Sex: 1-9 2019 4,070
OVC_SERV Age/Sex: 10-14 Female 2019 2,719
OVC_SERV Age/Sex: 10-14 Male 2019 1,566
OVC_SERV Age/Sex: 15-17 Female 2019 1,999
OVC_SERV Age/Sex: 15-17 Male 2019 909
OVC_SERV By: Age/sex: 18-24 Female 2019 1,401
OVC_SERV By: Age/sex: 25+ Female 2019 23
OVC_SERV By: Age/sex: Male 18-24 2019 589
OVC_SERV By: Age/sex: Male 25+ 2019 7
OVC_SERV Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2019 13,419
OVC_SERV Program Completion: Active 2019 13,269
OVC_SERV Program Completion: Graduation 150 Number of orphans and vulnerable children (<18 years old) whose HIV status is known or unknown by the OVC implementing partner. 11,943 Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS 2019 13,419
OVC_SERV Sum of Age/Sex disaggregates 2019 7,193
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2019 158
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 158
PMTCT_EID Sum of Infant Age disaggregates 2019 158
PrEP_NEW 25-29, Female 2019 1
PrEP_NEW 25-29, Male 2019 1
PrEP_NEW 30-34, Female 2019 1
PrEP_NEW 30-34, Male 2019 1
PrEP_NEW 35-39, Female 2019 1
PrEP_NEW 35-39, Male 2019 1
PrEP_NEW 40-49, Female 2019 1
PrEP_NEW 40-49, Male 2019 1
PrEP_NEW Female 15-19 2019 3
PrEP_NEW Female 20-24 2019 9
PrEP_NEW FSW 2019 3
PrEP_NEW Male 20-24 2019 1
PrEP_NEW MSM 2019 1
PrEP_NEW Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection 2019 21
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 16
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 22
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 37
TB_PREV By Age/Sex (Numerator): <15, Female 2019 11
TB_PREV By Age/Sex (Numerator): <15, Male 2019 13
TB_PREV By Age/Sex (Numerator): 15+, Female 2019 148
TB_PREV By Age/Sex (Numerator): 15+, Male 2019 78
TB_PREV The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 250
TB_PREV The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 537
TB_PREV_den By Age/Sex (Denominator): <15, Female 2019 22
TB_PREV_den By Age/Sex (Denominator): <15, Male 2019 23
TB_PREV_den By Age/Sex (Denominator): 15+, Female 2019 318
TB_PREV_den By Age/Sex (Denominator): 15+, Male 2019 174
TB_PREV_den IPT, Life-long ART, New, Positive 2019 537
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 2
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 15
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 21
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 37
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2019 37
TB_STAT_den Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 2
TB_STAT_den Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 15
TB_STAT_den Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 21
TX_CURR 25-29, Female, Positive 2019 251
TX_CURR 25-29, Male, Positive 2019 81
TX_CURR 30-34, Female, Positive 2019 190
TX_CURR 30-34, Male, Positive 2019 122
TX_CURR 35-39, Female, Positive 2019 190
TX_CURR 35-39, Male, Positive 2019 122
TX_CURR 40-49, Female, Positive 2019 133
TX_CURR 40-49, Male, Positive 2019 122
TX_CURR Age/Sex: <1 2019 32
TX_CURR Age/Sex: <1-9 2019 1,023
TX_CURR Age/Sex: 10-14 Female 2019 572
TX_CURR Age/Sex: 10-14 Male 2019 530
TX_CURR Age/Sex: 15-19 Female 2019 45
TX_CURR Age/Sex: 15-19 Male 2019 25
TX_CURR Age/Sex: 20-24 Female 2019 127
TX_CURR Age/Sex: 20-24 Male 2019 34
TX_CURR Age/Sex: 50+ Female 2019 115
TX_CURR Age/Sex: 50+ Male 2019 45
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2019 3,750
TX_CURR Sum of age/sex disaggregates 2019 70
TX_NEW 25-29, Female, Positive 2019 1
TX_NEW 25-29, Male, Positive 2019 6
TX_NEW 30-34, Female, Positive 2019 3
TX_NEW 30-34, Male, Positive 2019 6
TX_NEW 35-39, Female, Positive 2019 1
TX_NEW 35-39, Male, Positive 2019 4
TX_NEW 40-49, Female, Positive 2019 1
TX_NEW 40-49, Male, Positive 2019 3
TX_NEW Breastfeeding status 2019 1
TX_NEW By Age/Sex: <1 2019 33
TX_NEW By Age/Sex: 1-9 2019 19
TX_NEW By Age/Sex: 10-14 Female 2019 2
TX_NEW By Age/Sex: 10-14 Male 2019 3
TX_NEW By Age/Sex: 15-19 Female 2019 16
TX_NEW By Age/Sex: 15-19 Male 2019 5
TX_NEW By Age/Sex: 20-24 Female 2019 37
TX_NEW By Age/Sex: 20-24 Male 2019 16
TX_NEW By Age/Sex: 50+ Male 2019 1
TX_NEW FSW 2019 2
TX_NEW MSM 2019 1
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 159
TX_NEW People in prisons and other enclosed settings 2019 1
TX_NEW Pregnancy status 2019 12
TX_NEW Sum of Age/Sex disaggregates 2019 80
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2019 4,237
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted 2019 1,285
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: <15 Male Routine 2019 1,241
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine 2019 873
TX_PVLS_den Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine 2019 838
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 88
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 40
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 333
TX_RET Numerator by Status: Breastfeeding 2019 6
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 368
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 151
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 69
TX_RET_den Denominator by Status: Breastfeeding 2019 5
TX_RET_den Denominator by Status: Pregnant 2019 31
TX_TB Number of ART patients who were screened for TB at least once during the reporting period 2019 3,729
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Female 2019 95
TX_TB_den Denominator: By Aggregated Age/Sex: <15, Male 2019 93
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Female 2019 2,406
TX_TB_den Denominator: By Aggregated Age/Sex:15+, Male 2019 1,138
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 83
TX_TB_den Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 35
TX_TB_den Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 122
Cross Cutting Budget Categories and Known Amounts Total: $584,536
Economic Strengthening $259,794
Education $194,845
Food and Nutrition: Commodities $129,897